Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Shares Issued
Ratios

Immuneering (IMRX) Shares Outstanding (2020 - 2024)

Immuneering has reported Shares Outstanding over the past 5 years, most recently at $31.1 million for Q3 2024.

  • Quarterly results put Shares Outstanding at $31.1 million for Q3 2024, up 6.09% from a year ago — trailing twelve months through Sep 2024 was $31.1 million (up 6.09% YoY), and the annual figure for FY2023 was $29.3 million, up 10.8%.
  • Shares Outstanding for Q2 2024 was $29.7 million at Immuneering, roughly flat from $29.7 million in the prior quarter.
  • Over the last five years, Shares Outstanding for IMRX hit a ceiling of $29.7 million in Q1 2024 and a floor of $5.0 million in Q2 2020.
  • Median Shares Outstanding over the past 5 years was $26.4 million (2022), compared with a mean of $20.6 million.
  • Biggest five-year swings in Shares Outstanding: surged 432.98% in 2022 and later rose 0.43% in 2023.
  • Immuneering's Shares Outstanding stood at $5.0 million in 2020, then skyrocketed by 423.99% to $25.9 million in 2021, then rose by 1.85% to $26.4 million in 2022, then grew by 10.8% to $29.3 million in 2023, then increased by 6.08% to $31.1 million in 2024.
  • The last three reported values for Shares Outstanding were $31.1 million (Q3 2024), $29.7 million (Q2 2024), and $29.7 million (Q1 2024) per Business Quant data.